 |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||
National Health Insurance
|
|||||||||||||||
|
Health services that do not require hospitalisation. |
|
Medical conditions that tend to last indefinitely and tend to be degenerative in nature where treatment or medication aims to manage rather than to cure. |
|
The likelihood of medical care expenses occurring. This is usually measured according to age and sex. |
|
The likelihood of death occurring. |
|
When used by doctors, factors that may predict the likelihood of an individual having a health event. As in the risk factors for diabetes include obesity. Frequently misunderstood when medical professionals talk to healthcare financing people. See risk and risk factors under health insurance terms below. |
|
WHO definition: an infectious bacterial disease caused by Mycobacterium tuberculosis, which most commonly affects the lungs. It is transmitted via droplets from the throat and lungs of people with the active respiratory disease. In healthy people, the infection often causes no symptoms, since the person's immune system acts to “wall off” the bacteria. Tuberculosis is treatable with a six-month course of antibiotics. HIV is the main reason for failure to meet TB control targets in high HIV settings. TB is a major cause of death among people living with HIV/AIDS. |
|
WHO definition: one in three people in the world is infected with dormant TB bacteria. Only when the bacteria become active do people become ill with TB and it can usually be treated with a course of four standard, or first-line, anti-TB drugs. If these drugs are misused or mismanaged, multidrug-resistant TB (MDR-TB) can develop. MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects. Extensively drug-resistant TB (XDR-TB) can develop when these second-line drugs are also misused or mismanaged and therefore also become ineffective. Because XDR-TB is resistant to first- and second-line drugs, treatment options are seriously limited. |
Contact Details:
Innovative Medicines SA
Val Beaumont
P.O. Box 2008
Houghton, 2041
Tel: +27 11 880-4644
Fax: +27 11 880-5987
